Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Channer

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Nursing Times|July 10, 1985
Stand up and take your medicineK Channer
Health Trends|December 10, 1990
Echocardiography or cardiac catheterisation--a comparison of risks, benefits and costsK Channer, E Robertson
BMJ (Clinical Research Ed.)|January 18, 1997
Predicting adverse cardiac events after myocardial infarction and thrombolysis. Study does not justify replacement of exercise testing with radionuclide imagingS Grant, R Steeds, K Channer
Frontiers of Hormone Research|November 18, 2008
Testosterone in chronic heart failureC Malkin, T Jones, K Channer
Journal of Cardiovascular Pharmacology|December 30, 1998
Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failureL O'Toole, M Stewart, P Padfield, et al.
Frontiers of Hormone Research|November 18, 2008
Testosterone and coronary artery diseaseJ Nettleship, R Jones, K Channer, et al.
American Journal of Hypertension|March 4, 2000
Analysis of promoter region polymorphism in the aldosterone synthase gene (CYP11B2) as a risk factor for myocardial infarctionS Patel, R Steeds, K Channer, et al.
Thrombosis and Haemostasis|June 3, 1998
Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjectsR Steeds, M Adams, P Smith, et al.
Circulation|August 15, 1996
A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarctionN J Samani, J R Thompson, L O'Toole, et al.
European Urology|February 21, 1998
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study GroupC J Tyrrell, L Denis, D Newling, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Nursing Times|July 10, 1985
Stand up and take your medicineK Channer
Health Trends|December 10, 1990
Echocardiography or cardiac catheterisation--a comparison of risks, benefits and costsK Channer, E Robertson
BMJ (Clinical Research Ed.)|January 18, 1997
Predicting adverse cardiac events after myocardial infarction and thrombolysis. Study does not justify replacement of exercise testing with radionuclide imagingS Grant, R Steeds, K Channer
Frontiers of Hormone Research|November 18, 2008
Testosterone in chronic heart failureC Malkin, T Jones, K Channer
Journal of Cardiovascular Pharmacology|December 30, 1998
Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failureL O'Toole, M Stewart, P Padfield, et al.
Frontiers of Hormone Research|November 18, 2008
Testosterone and coronary artery diseaseJ Nettleship, R Jones, K Channer, et al.
American Journal of Hypertension|March 4, 2000
Analysis of promoter region polymorphism in the aldosterone synthase gene (CYP11B2) as a risk factor for myocardial infarctionS Patel, R Steeds, K Channer, et al.
Thrombosis and Haemostasis|June 3, 1998
Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjectsR Steeds, M Adams, P Smith, et al.
Circulation|August 15, 1996
A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarctionN J Samani, J R Thompson, L O'Toole, et al.
European Urology|February 21, 1998
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study GroupC J Tyrrell, L Denis, D Newling, et al.
Pageof 2